Online Master's in Biomedical Engineering @ Case.edu
A Mighty Force - read full story

Available Technologies

For information on technology available for licensing or commercialization, awards, or project information, please contact the CCTRP program leadership and we would be pleased to answer any questions you may have. This is a partial list, so please feel free to contact the team to learn more about these or additional opportunities. When available, technologies with one-page overviews are linked to the technology title.

Additional technologies from the Coulter Network can be found here.

Here is a link to setup an easy 30 min phone call: https://calendly.com/fening/30min-zoom

Quick links: Devices | Diagnostics | Healthcare IT | Therapeutics


Devices

 

 

Minimally invasive interfascicular nerve stimulation (MiiNS) system for chronic pain management

Dustin Tyler, Kent H. Smith Professor, biomedical engineering; and Jennifer Sweet, professor, neurological surgery

This is a drug-free technology to provide targeted, comfortable, worry-free relief to people suffering from long-term pain. The discomfort and emotional stress from pain affects a person’s activity, sleep, and ability to live a healthy life, leading to other serious health problems. Our Minimally Invasive Interfascicular Nerve Stimulation (MiiNS) technology provides a targeted, personally customized and comfortable treatment without side effects, addiction or surgical procedures. MiiNS can be implanted by a doctor during a simple office visit to provide long lasting pain relief.

 

3-D ultrasound imaging for ophthalmology

Faruk Orge, professor of ophthalmology and visual sciences at the School of Illustration of high-resolution, 3D microscopic ultrasound systemMedicine and pediatric division chief of ophthalmology at University Hospitals Cleveland Medical Center; and David Wilson, professor of biomedical engineering

This technology will be the first high-resolution, 3-D microscopic ultrasound system to provide novel visualizations of eye structures to better understand pathophysiology, plan treatments and assess treatment results. Ultrasound is an effective ophthalmic imaging method that allows structures behind the iris, including the lens and ciliary body, as well as key portions of the aqueous outflow system, to be seen. This region of the eye plays a critical role in glaucoma—which affects over 2.7 million people in the United States alone—and cataract, which are leading causes of reversible and irreversible blindness.
 

Oropharynx appliance to maintain airway patency (OPTIONED)

Dominique Durand, the Elmer Lincoln Lindseth Professor in Biomedical Engineering; and Kingman Strohl, professor of physiology and biophysics.

Obstructive sleep apnea (OSA) negatively impacts the health of millions of Americans, and the problem continues to grow. Sleep apnea is often cited among areas to address to reduce health-care spending and improve chronic disease management.

Non-invasive treatment options have been effective, but patients often choose to not use them because they’re uncomfortable and inconvenient.

The team’s novel technology is a device to treat OSA in a form expected to deliver much higher patient compliance. The project aims to test the new design for the treatment of OSA.

The device will be first tested in five patients for compliance in a home setting, and then undergo sleep tests at night to determine the device’s effectiveness at reducing the apnea-hypopnea index.

 


Diagnostics

 

 

TraumaChek: A field-deployable dielectric coagulometer for comprehensive assessment of trauma-induced coagulopathy

Anirban Sen Gupta, professor biomedical engineering; and Sanjay Ahuja, professor of pediatrics

TraumaChekTM is a miniaturized, multichannel, portable, handheld blood coagulation analyzer for early, rapid, and comprehensive assessment of trauma-induced coagulopathy to guide hemorrhage control, transfusion, and resuscitative management of trauma at the point-of-injury by first responders and at the point-of-care by hospital clinicians.

 

Novel positron emission tomography (PET) imaging agent for tumor detection and treatment

Susann Brady-Kalnay, professor of molecular biology and microbiology; and James Basilion, professor of radiology biomedical engineering and pathology.

Specific tumor detection is critically important in cancer imaging to avoid unnecessary biopsies to exclude false-positive findings and to allow treatment—or redirection of treatment—at earlier stages of the disease. Positron Emission Tomography (PET) imaging agents that specifically recognize tumor cells are necessary for improved imaging and subsequent evaluation of therapeutic efficacy independent of their metabolic rates. PTPµ is a novel imageable biomarker that can be used to specifically and more comprehensively detect and monitor aggressive invasive and metastatic tumors.

 

Point-of-care device for monitoring and diagnosis of oral cancer

Aaron Weinberg, associate dean for research, chair of the Department of Biological Sciences and professor; Umut Gurkan, assistant professor of mechanical and aerospace engineering; and Santosh Ghosh, senior research associate.

Oral cancer kills thousands in the United States and hundreds of thousands worldwide. Early detection is key to improved survival. Oral cancer is now diagnosed by tissue biopsy, followed by pathology review.

But biopsies are expensive, painful, can cause complications and are impractical, should monitoring be required.

The team’s novel technology builds on a recent discovery that the two proteins produced in early stages of oral cancer change their ratios in cancerous cells, and that the ratio could be used as a non-invasive diagnostic tool. The researchers have developed a point-of-care microfluidic device which, when connected to a smartphone, obtains ratio results within 15 minutes.

Advantages include the ability to: non-invasively swab and diagnose a lesion for cancer while the patient waits; determine if a biopsy is necessary; permit pre-malignant lesions to be monitored; perform the test in any dental or ear, nose and throat clinic as part of oral health check-up; and obtain results at one-tenth the cost of a biopsy and pathology review.

 

Robust nanobubble contrast agents for real-time ultrasound guided prostate cancer biopsy

Agata Exner, professor of radiology and biomedical engineering; and Jim Basilion, professor of radiology and biomedical engineering

This technology will enable a more efficient and effective prostate cancer diagnosis while building on the existing biopsy workflow and clinical ultrasound imaging technology. The nanobubble imaging agent will specifically target prostate cancer cells and serve as a beacon guiding the urologist, in real time, to possible tumors. Nanobubble-guided biopsies could identify tumors more accurately and could lead to fewer procedures, thus reducing risk, lowering costs and shortening the time to diagnosis and treatment.

 

CorCalDx: dual energy X-ray coronary calcium scoring

David Wilson; Robert Gilkeson

This software enables fast and high throughput detection of coronary calcium using the commonly ordered dual-energy chest X-ray exams. An excellent biomarker for coronary artery disease, coronary calcium scoring has long been assessed using expensive computed tomography. As the chest X-ray is the most common medical imaging procedure by far, CorCalDx will help radiologists screen for coronary calcium and identify coronary artery disease risk with little or no additional cost or radiation.

 

Sickle cell disease biochip blood-cell adhesion test for emerging anti-adhesive therapies (OPTIONED)

Umut Gurkan, assistant professor of mechanical and aerospace engineering; and Jane Little, professor of medicine in the Department of Hematology and Oncology

Sickle cell disease biochip technology is a new microfluidic blood test that measures the stickiness of blood cells to blood vessel walls. This new blood test can be used as a companion diagnostic test platform for emerging anti-adhesive therapies to allow effective, personalized treatment and care for patients living with sickle cell disease.

 


Healthcare IT

 

LunIOTx: decision-support technology for predicting response to immunotherapy in lung cancer

Anant Madabhushi, the F. Alex Nason Professor II of biomedical engineering and director of the Center for Computational Imaging and Personalized Diagnostics

LunIOTx is a non-invasive decision-support technology that uses patented artificial intelligence and pattern recognition algorithms on routine CT scans to identify lung cancer patients who will or will not respond to immunotherapy. By identifying patterns on CT scans associated with response, LunIOTx can enable early identification of lung cancer patients in whom expensive immunotherapy can be avoided and who might be better candidates for chemo or radiation therapy.

 

LunIRiS: Decision support tool for lung nodule risk prediction on screening CT

Anant Madabhushi, the F. Alex Nason Professor II of biomedical engineering; and Robert Gilkeson, professor of radiology.

Each year, more than 20 million patients in the United States undergo a chest computer tomography (CT) exam. In nearly half of these exams, a pulmonary nodule will be identified.

While most of these nodules are benign, it is difficult to distinguish them from nodules that require treatment. As a result, many patients unnecessarily undergo more invasive diagnostic procedures, including surgical wedge resection.

The team’s novel technology, LunIRiS, is a computerized decision-support technology for use in conjunction with routine chest CT scans to reduce the high false-positive diagnostic rate associated with lung nodules. The technology could greatly reduce the number of unnecessary invasive diagnostic procedures. With advanced computational image-analytic and machine-learning tools, LunIRiS provides a risk score for improved quantitative assessment of lung nodules and has been shown to improve the diagnostic accuracy of human readers.

 


Therapeutics

 

BAFF CAR-NK cells for therapy of B cell malignancies

Reshmi Parameswaran, assistant professor, medicine; and Pallavi Tiwari, assistant professor, biomedical engineering

BAFF CAR-­NK cells can specifically kill B cell cancers in a very effective manner with minimum side effects. This is a potential curative therapeutic strategy to address patients who are not responding to the current treatment methods.

 

 

 

BG34-200: a potent immunotherapeutic for melanoma, osteosarcoma, pancreatic cancer and other solid tumor cancers

Mei Zhang, research assistant professor, biomedical engineering; and Alex Huang, professor of pediatrics and pathology

A significant fraction of patients with solid tumor cancers in metastatic and advanced settings do not respond to immunotherapies due to a lack of T-cell-inflamed tumor microenvironment. This botanical-derived non-toxic BG34-200 molecule can be intravenously injected to modulate macrophages and create a tumor microenvironment that is vital for the generation of antitumor T-cell responses. The team is launching a clinical trial targeting canine metastatic osteosarcoma (OS) to collect key and gap data in preparation for a First-In-Human clinical trial targeting pediatric and AYA OS.

 

NeutroStat: neutrophil-targeted nanomedicine for treating venous thromboembolism (VTE)

Evi Stavrou, an Oscar D. Ratnoff Designated Professor in Medicine and Hematology.; and Anirban Sen Gupta, professor of biomedical engineering

NeutroStat is a nanomedicne technology that targets neutrophil-platelet complexes at the site of growing venous thrombi for site-specific delivery of therapeutic molecules to reduce neutrophil extracellular trap formation. Currently, venous thrombi are treated by downstream anticoagulant therapies that are associated with systemic bleeding risks in many patients. NeutroStat promises to reduce the upstream mechanisms that drive coagulation and thrombus formation, in a highly targeted fashion, that will significantly improve therapeutic safety and efficacy in the treatment of venous thromboembolism.

 

Drug-Free targeted prostate cancer treatment with TNT (Targeted Nanobubble Therapy)

Agata Exner, professor of radiology and biomedical engineering; and Jim Basilion, professor of radiology and biomedical engineering

 

 

 

 

 

 

Drug free, low toxicity prostate cancer treatment using nanobubbles are targeted to the prostate specific membrane antigen (PSMA) biomarker overexpressed on prostate tumor cells. The nanobubbles are injected into the bloodstream and specifically seek out only the cancer cells. Once inside the target cell, the NBs remain trapped and can be excited with an ultrasound pulse. Exposure to ultrasound results in collapse of the bubbles, leading to a highly focused mechanical disruption of the cancer cells and cell death. The approach, which we call TNT – targeted nanobubble therapy - can fit into the existing clinical work flow and can be carried out with standard clinical ultrasound equipment. TNT can treat tumors without severe side effects, as it will be effective only when NBs are sonicated and will destroy only the cancer cells and not the surrounding healthy cells.

 

Photosorb: engineered sunscreen with single, multifunctional active ingredient

Vijay Krishna, assistant staff in Cleveland Clinic’s Department of Biomedical Engineering; and Edward Maytin, staff in Cleveland Clinic’s Department of Dermatology

Every year, more than one million new cases of skin cancer, including melanoma, are diagnosed in the United States. The primary cause is exposure to ultraviolet radiation (UV) from sunlight. Sunscreens can block UV, but increasing concerns about the health and environmental risks of chemical sunscreens now on the market underscores an urgent need for safer, more effective alternatives. A team from biomedical engineering and dermatology at Cleveland Clinic is developing a novel sunscreen (PhotoSorb) that appears to be safer and more stable than current sunscreens, and also has the potential to actually prevent skin cancers.

 

Plant virus-like particle-based cancer immunotherapy (OPTIONED)

Nicole Steinmetz, Julian Kim

The researchers developed an “in situ vaccination” strategy to treat metastatic cancer, using a nanoparticle formed by the protein components of a plant virus. Direct administration of the therapeutic nanoparticle into identified tumors triggers a tumor-specific immune response, eradicating the treated tumor as well as distal metastatic sites. Immune memory protects patients from outgrowth of metastatic disease or recurrence. Support from CTTRP will provide a framework toward translation from preclinical models to clinical evaluation.